Bushu and Suzuken team up to support manufacturers eyeing up Japanese market
The new business alliance will support new product launches for specialty pharmaceutical manufacturers looking to enter the Japanese market
Contract manufacturer Bushu Pharmaceuticals has signed a business agreement with Suzuken, to offer support services for new product launches for specialty pharmaceutical manufacturers looking to enter the Japanese market.
The alliance between the two firms will establish a one-stop logistics centre in Soka City, Saitama Prefecture, for manufacturing operations and general logistics.
Bushu Pharma will be able to conduct contract manufacturing operations from the site and the two companies will work together to offer one-stop services for specialty pharmaceuticals, including marketing authorisation holder/drug approval holder consulting, import, inspection, manufacturing, storage (manufacturer logistics), wholesale distribution, post-marketing survey, and patient support.
In addition, through the use of the Cubixx specialty drug traceability system, developed by Suzuken, Bushu Pharma will provide delivery of products all the way to patients.
The alliance also enables Bushu Pharma to utilize the 1,465-m2 cold storage area newly established within the Kazo Pharmaceutical Joint Distribution Center of Chuo Unyu, a subsidiary of Suzuken. The area will make it possible for Bushu Pharma to carry out contract manufacturing centered on secondary packaging such as inspection, labelling, and packaging.
Furthermore, the two companies, including S.D. Collaboration Co. (another Suzuken subsidiary), have also started joint proposal sales efforts to specialty pharmaceutical manufacturers who are planning to enter the Japanese market, led through Bushu Pharma’s US office in North Carolina.
In recent years, the number of innovative specialty pharmaceuticals on the market that require strict temperature, inventory, and security control has been increasing, as has the number of pharmaceutical manufacturers looking to introduce these products to Japan. These manufacturers, however, frequently lack the required assets such as manufacturing plants, distribution centres and networks necessary to enter the Japanese market with minimal resources and, therefore, must outsource these functions.
Suzuken possesses a distribution network in Japan that can support the international transportation of specialty pharmaceuticals. Bushu Pharma has been contract manufacturing in Japan for more than 20 years, holds GMP certifications from all over the world, and has a track record of exporting to more than 43 countries.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance